重要内容提示： 每股现金红利0.096元 相关日期 | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/6/20 | 2025/6/23 | 2025/6/23 | 一、 通过分配方案的股东大会届次和日期 证券代码：688166 证券简称：博瑞医药 公告编号：2025-034 博瑞生物医药（苏州）股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本次利润分配方案经公司2025 年 5 月 19 日的2024年年度股东大会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 差异化分红送转方案： （1）差异化分红方案 是否涉及差异化分红送转：是 每股分配比例 1. 发放年度：2024年年度 2. 分派对象： 2025 年 5 月 19 日，公司召开 2024 年年度股东大会审议通过了《2024 年年度 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 证券代码：688166 证券简称：博瑞医药 公告编号：2025-036 博瑞生物医药（苏州）股份有限公司 关于调整 2024 年度利润分配现金分红总额的公告 现金分红总额调整情况：博瑞生物医药（苏州）股份有限公司（以下简 称"公司"）拟维持每股派发现金红利 0.096 元（含税）不变，派发现金红利总 额由 40,522,181.28 元（含税）调整为 40,550,859.17 元（含税）。 本次调整原因：自 2025 年 3 月 31 日至本公告披露日，因公司发行的可 转换公司债券"博瑞转债"转股，公司总股本变更为 422,768,244 股，扣除公司 回购专用证券账户中股份 363,461 股，本次实际参与利润分配的股本数变更为 422,404,783 股。公司按照维持每股分配比例不变的原则，对分配总额进行相应 调整。 2025 年 4 月 1 日，公司召开第四届董事会第四次会议审议通过了《2024 年 年度利润分配预案》，并经 2025 年 5 月 19 ...

博瑞医药公告，公司拟以2000万元认购苏州极客基因科技有限公司新增注册资本，增资后将取得极客基 因4.1667%股权。此次交易构成关联交易，未构成重大资产重组。 ...

Group 1 - The core viewpoint highlights a strong performance in the Chinese innovative pharmaceutical sector, with the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index rising by 2.72% as of June 12, 2025, driven by significant gains in constituent stocks such as Rongchang Bio (+17.55%) and BeiGene (+8.00%) [1] - A total of 53 new drugs were approved in China from the beginning of 2025 to the end of May, including 30 domestic innovative drugs and 23 imported ones, covering various therapeutic areas such as oncology and rare diseases [1] - The Chinese innovative drug market is projected to reach nearly 550 billion RMB in 2024, with an expected explosive growth driven by business development (BD) revenues from 2025 to 2027, and is anticipated to exceed 2 trillion RMB by 2030 [1] Group 2 - The Sci-Tech Innovation Board Biopharmaceutical Index consists of 50 large-cap companies from various sectors, including biopharmaceuticals and biomedical engineering, reflecting the overall performance of representative companies in the industry [2] - As of May 30, 2025, the top ten weighted stocks in the index accounted for 51.6% of the total index weight, with companies like United Imaging Healthcare and BeiGene among the leading constituents [2]

A股创新药概念再度活跃，奥赛康封板涨停，博瑞医药、睿智医药涨超10%，海思科、长春高新、微芯 生物、舒泰神等跟涨。 ...

Core Viewpoint - The performance of the Sci-Tech Innovation Pharmaceutical Index ETF has shown significant growth in both trading volume and scale, indicating strong investor interest and confidence in the sector [3][5][6]. Liquidity - The Sci-Tech Innovation Pharmaceutical Index ETF had an intraday turnover of 9.12%, with a transaction volume of 20.17 million yuan. Over the past week, the average daily transaction volume reached 50.98 million yuan, ranking first among comparable funds [3]. Scale - In the past year, the Sci-Tech Innovation Pharmaceutical Index ETF's scale increased by 143 million yuan, achieving notable growth and ranking first among comparable funds [3]. Shares - The ETF's shares grew by 120 million in the past year, also ranking first among comparable funds [3]. Top Holdings - As of May 30, 2025, the top ten weighted stocks in the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index accounted for 51.6% of the total weight. The leading stocks include: - United Imaging Healthcare (8.97%) - BeiGene (7.05%) - Huaitai Medical (5.85%) - Aierx (4.91%) - Baillie Tianheng (4.77%) - Zai Lab (4.75%) - BGI Genomics (4.17%) - Junshi Biosciences (4.15%) - Aibo Medical (3.33%) - Teva Biopharma (3.25%) [5]. Market Response - Following the American Society of Clinical Oncology (ASCO) annual meeting, there has been a positive market response, highlighting the competitiveness and innovation of Chinese pharmaceutical companies in new drug development [5][6]. Innovation Pipeline - The proportion of domestic companies' innovative drug data presented at ASCO has been increasing, with 73 studies selected for oral presentations in 2025, indicating a strong focus on innovation within the industry [6]. Investment Opportunities - Investors without stock accounts can access opportunities in the Sci-Tech Innovation Board biopharmaceutical sector through the Sci-Tech Biopharmaceutical ETF linked fund (021061) [6].

Group 1: Liquidity and Performance of Sci-Tech Pharmaceutical Index ETF - The Sci-Tech Pharmaceutical Index ETF had a turnover rate of 16.48% during the trading session, with a transaction volume of 37.98 million yuan, indicating active market trading [2] - Over the past week, the average daily transaction volume of the ETF reached 48.92 million yuan, ranking first among comparable funds [2] - In the past year, the ETF's scale increased by 154 million yuan, achieving significant growth and ranking first in new scale among comparable funds [2] - The ETF's shares grew by 130 million units in the past year, also ranking first in new shares among comparable funds [2] - As of June 10, the net value of the ETF increased by 25.51% over the past year [2] - The highest monthly return since inception was 23.29%, with the longest consecutive monthly gains being 4 months and a maximum increase of 21.76% [2] - The average monthly return during the rising months was 8.18%, with a historical one-year profit probability of 69.81% [2] Group 2: Market Trends and Investment Opportunities - The Central Committee of the Communist Party of China and the State Council issued opinions to improve the basic medical insurance drug catalog adjustment mechanism and to develop a commercial health insurance innovative drug catalog [3] - A report from Dongwu Securities indicated that there were 73 oral presentations from China at the 2025 ASCO, marking a historical high, with 89 out of 184 ADC pipeline studies coming from China, accounting for approximately 48.4% of the total [3] - The agency believes that the competitiveness of domestic innovative drugs in the global market is continuously improving, and international investors' confidence in Chinese innovative drug companies is increasing [3] - Domestic innovative drugs are transitioning from "catching up" to "leading," presenting significant investment opportunities [3] - Investors without stock accounts can access the Sci-Tech Biopharmaceutical ETF linked fund (021061) to capitalize on opportunities in the Sci-Tech Board biopharmaceutical sector [3]

Group 1 - The company, BrightGene Bio-Medical Technology Co., Ltd., issued convertible bonds totaling RMB 465 million, with a net fundraising amount of RMB 456.83 million after deducting issuance costs [3][18]. - The bonds have a maturity period of six years, from January 4, 2022, to January 3, 2028, with a face value of RMB 100 per bond [3][4]. - The coupon rates for the bonds are structured to increase over the years, starting at 0.4% in the first year and reaching 3% in the sixth year [3][4]. Group 2 - The company reported a revenue of RMB 1.28 billion for the fiscal year 2024, representing an 8.74% increase from the previous year [17]. - The net profit attributable to shareholders decreased by 3.12% to RMB 180.51 million, primarily due to increased R&D expenses [17]. - The company’s total assets increased by 2.63% to RMB 5.16 billion, indicating stable growth in its financial position [17]. Group 3 - The company focuses on innovative pharmaceutical development, emphasizing original drugs and complex formulations to meet unmet clinical needs globally [15][16]. - Key therapeutic areas include antiviral, antifungal, immunosuppressive, respiratory, oncology, and metabolic diseases, with core products in each category [16]. - The company has a strong commitment to R&D, with R&D expenses increasing by 19.65% year-on-year, reflecting its strategy of being research-driven [17]. Group 4 - The bonds are rated AA- by Dongfang Jincheng International Credit Rating Co., Ltd., with a stable outlook, indicating a strong credit profile [5][21]. - The company has established a dedicated fund management system to ensure the proper use of raised funds, adhering to regulatory requirements [20]. - The company has not experienced any defaults on bond repayments, demonstrating a stable repayment capability [21].

证券代码：688166 债券代码：118004 证券简称：博瑞医药 债券简称：博瑞转债 博瑞生物医药（苏州）股份有限公司 向不特定对象发行可转换公司债券 受托管理事务报告 （2024年度） 债券受托管理人 （中国（上海）自由贸易试验区浦明路 8 号） 二〇二五年六月 重要声明 本报告依据《可转换公司债券管理办法》（以下简称"《管理办法》"）、 《博瑞生物医药（苏州）股份有限公司（发行人）与民生证券股份有限公司（受 托管理人）签订的科创板向不特定对象发行可转换公司债券之受托管理协议》 （以下简称"《受托管理协议》"）、《博瑞生物医药（苏州）股份有限公司向不 特定对象发行可转换公司债券募集说明书》（以下简称"《可转债募集说明 书》"）、《博瑞生物医药（苏州）股份有限公司2024年年度报告》等相关公开 信息披露文件、第三方中介机构出具的专业意见等，由本次债券受托管理人民生 证券股份有限公司（以下简称"民生证券"）编制。民生证券对本报告中所包含 的从上述文件中引述内容和信息未进行独立验证，也不就该等引述内容和信息的 真实性、准确性和完整性做出任何保证或承担任何责任。 本报告不构成对投资者进行或不进行某项行为的推荐意见 ...

沪指6月9日上涨0.43%，申万所属行业中，今日上涨的有30个，涨幅居前的行业为医药生物、农林牧 渔，涨幅分别为2.30%、1.72%。医药生物行业位居今日涨幅榜首位。跌幅居前的行业为食品饮料，跌 幅分别为0.43%。 资金面上看，两市主力资金全天净流入35.37亿元，今日有16个行业主力资金净流入，非银金融行业主 力资金净流入规模居首，该行业今日上涨1.20%，全天净流入资金27.81亿元，其次是医药生物行业，日 涨幅为2.30%，净流入资金为20.27亿元。 医药生物行业今日上涨2.30%，全天主力资金净流入20.27亿元，该行业所属的个股共475只，今日上涨 的有435只，涨停的有16只；下跌的有36只。以资金流向数据进行统计，该行业资金净流入的个股有251 只，其中，净流入资金超亿元的有5只，净流入资金居首的是华海药业，今日净流入资金2.78亿元，紧 随其后的是睿智医药、众生药业，净流入资金分别为2.48亿元、2.47亿元。医药生物行业资金净流出个 股中，资金净流出超亿元的有5只，净流出资金居前的有恒瑞医药、千红制药、博瑞医药，净流出资金 分别为2.88亿元、1.18亿元、1.07亿元。（数据宝） | ...